173 related articles for article (PubMed ID: 29393493)
21. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
22. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
23. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Tewari KS; Eskander RN; Monk BJ
Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
[TBL] [Abstract][Full Text] [Related]
24. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin.
Deng M; Sun J; Xie S; Zhen H; Wang Y; Zhong A; Zhang H; Lu R; Guo L
Mol Med Rep; 2019 Sep; 20(3):2258-2266. PubMed ID: 31322224
[TBL] [Abstract][Full Text] [Related]
26. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
Fleury H; Carmona E; Morin VG; Meunier L; Masson JY; Tonin PN; Provencher D; Mes-Masson AM
Oncotarget; 2017 Jun; 8(25):40152-40168. PubMed ID: 27374179
[TBL] [Abstract][Full Text] [Related]
27. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
28. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
29. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
31. Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib.
Gong L; Tang Y; Jiang L; Tang W; Luo S
J Immunol Res; 2022; 2022():4065580. PubMed ID: 35910852
[TBL] [Abstract][Full Text] [Related]
32. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
33. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
34. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
[TBL] [Abstract][Full Text] [Related]
35. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
[TBL] [Abstract][Full Text] [Related]
36. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
[TBL] [Abstract][Full Text] [Related]
37. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
38. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
39. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Li Z; Wang Q; Zhang W; Yang Z; Li L
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
